The two confirmed cases of the virus in Daxing, a pharmaceutical speed reading agency, are new coronavirus variants found in the United Kingdom

January 20, 2021 / Medical Information List: 2 confirmed cases of the virus in Daxing District are new coronavirus variants found in the United Kingdom; Lilly/Merus has reached a $1.6 billion partnership; and CDK4/6 inhibitors approved clinically... Daily fresh medicine news, speed reading society and you pay attention to! Part1 Policy Brief Beijing added 7 locally confirmed cases 6 cases in Daxing 1 case from 0:00 to 24:00 on January 19 in Shunyi, Beijing added 7 new locally confirmed cases, no new suspected cases and asymptomatic infections;
six of the confirmed cases were in the Tiangongyuan street fusion community in Daxing District, and one in Nanxinzhuang do village in the town of Beiyi District.
, comprehensive epidemiological history, clinical manifestations, laboratory testing and imaging examination, the same day was diagnosed as a confirmed case, clinical type is common.
epidemiological investigation of the above-mentioned confirmed cases has been carried out and control measures have been put in place as required.
(CCTV News) Heilongjiang added 16 new confirmed cases of 31 new cases of asymptomatic infection January 19 0-24, Heilongjiang Province added 16 new confirmed cases of coronary pneumonia (Wangkui County, Wangkui City, where asymptomatic infection into a confirmed case of 1 case).
1 case was cured and discharged from hospital (Aihui District, Heihe City).
31 new cases of asymptomatic infection were reported (20 cases in Wangkui County, 2 cases in Anda City, 2 cases in Limin Development Zone in Harbin City, 2 cases in Hulan District of Harbin City, and 5 cases in Angxi District of Qiqihar City).
medical observation of asymptomatic infection 1 case (Aihui District, Heihe City).
(CCTV News) Jilin new local confirmed cases 46 cases Changchun City 10 cases Tonghua City 36 cases January 19 0-24 hours, the province added 46 new local confirmed cases (Changchun City 10 cases, Tonghua City 36 cases), of which 34 cases from the previously reported asymptomatic infected people into confirmed cases.
Up to now, the province has reported a cumulative total of 129 confirmed cases (35 cases in Changchun City, 94 cases in Tonghua City), of which 3 cases of critical heavy duty, 11 cases of heavy, 85 cases of ordinary type, light 30 cases.
as of 2400 hours on January 19, the province had reported a total of 267 locally confirmed cases, a total of 136 cases had been cured and discharged from hospital, 129 cases had been treated in isolation in hospital, and 2 cases had been fatal.
(CCTV News) Shenzhen has added a new case of asymptomatic infection of African imported new crown pneumonia, according to the Shenzhen Health and Health Commission, late on January 19, Shenzhen reported the addition of a new asymptomatic infection of new crown pneumonia imported from Africa, Hu, female, 32 years old, Chinese nationality, before entering Africa Congo (DRC) work.
examination, it was initially determined that Hu's close contact had 2 people, the close contact of 1 person, the above 3 people have been subjected to centralized isolation medical observation, nucleic acid test results are negative.
Department of Disease Control and Control is continuing to check hu's residence in Huide Building and carry out final disinfection.
(Shenzhen Health Committee) Hebei Yantai: 6 new confirmed cases, all in Nangong City on January 20 at 16:00, Yantai City held the 14th new crown pneumonia epidemic prevention and control press conference to introduce the situation.
meeting, the relevant person in charge of the introduction, as of January 20, 12 pm, the new six confirmed cases of neo-crown pneumonia, all in Nangong City, no new asymptomatic infection.
(CCTV News) Shijiazhuang City added 5 new cases of new corona pneumonia locally confirmed cases January 20 from 0:00 to 12:00, Shijiazhuang City added 5 new cases of locally confirmed cases of new crown pneumonia, distribution is 3 cases in the city, 2 cases in Xinle City, 3 cases of new crown pneumonia asymptomatic infection in Shijiazhuang City, 1 case in Xinle City, 1 case in Chang'an District, 1 case in Bridge West District.
(Caixin) Daxing District 2 confirmed cases of the virus for the United Kingdom found in the new coronavirus variant on the afternoon of January 20, in Beijing new coronavirus pneumonia outbreak prevention and control work at the 215th press conference, Beijing Center for Disease Control and Prevention Deputy Director Pang Xingfire introduced, January 19, the city CDC reported 2 locally confirmed cases of the new coronavirus samples, carried out genome-wide sequencing and analysis.
results suggest that the two cases are highly similar to the new coronavirus variant found in the UK.
reviewed by the China Center for Disease Control and Prevention, it is believed that the two confirmed cases of the virus is a new coronavirus variant found in the United Kingdom, the source of infection is initially determined to be imported from abroad.
(Beijing Daily) medical staff and other infected two hospitals were informed by the whole country on January 19, the National Health and Health Commission website published the State Council to deal with the new coronavirus pneumonia outbreak joint prevention and control mechanism integrated group of the "on Shijiazhuang City, Hebei Province, Lucheng People's Hospital, Xinle City Hospital, the new crown pneumonia outbreak hospital sense of weak prevention and control."
The Circular points out that in the response to the epidemic in Shijiazhuang City, Hebei Province, Shijiazhuang City People's Hospital, Xinle City Central Hospital have occurred medical personnel, inpatients and escorts, carers and other confirmed cases of neo-crown pneumonia, exposing the local implementation of medical institutions infection prevention and control measures, there is a major risk of spread of the epidemic, to the outbreak prevention and control of serious adverse effects.
(National Health and Health Commission) not old god medicine NMN was checked: the efficacy is exaggerated in China without the relevant license January 20, the State Administration of Market Supervision confirmed that the Bureau has issued "on the illegal operation of "not old medicine" letter" clearly in China NMN can not be produced and operated as food, and require the relevant operators to conduct a comprehensive inspection.
The document points out that the main components of "non-old medicine" for NMN or as raw materials for production, individual to tablet candy and other common forms of existence, mainly to promote "anti-aging, repair DNA, prevent Alzheimer's disease" and other roles.
, NMN has not obtained the license of medicine, health food, food additives and new food raw materials in China, that is, NMN can not be produced and operated as food.
(Beijing Daily) Medical Practitioners Law Amendment New Crown Pneumonia Epidemic Prevention and Control Experience Is proposed into the Law It is learned that at the 25th meeting of the Standing Committee of the 13th National People's Congress held on January 20, the Law on Medical Practitioners was amended to include the experience of prevention and control of the New Crown Pneumonia Outbreak into law. Draft
stipulates that the State shall establish a mechanism for the training and use of personnel adapted to the modern disease prevention and control system, that in case of emergency and national defense mobilization needs, physicians shall be subject to the dispatch of the competent departments of health and health, that physicians shall have the obligation to report infectious diseases, sudden and unexplained diseases and abnormal health events in a timely manner, and that doctors who have performed outstanding work in prevention, early warning, rescue and injury shall be recognized or rewarded.
(Caixin) Part2 production by observation CRO track line surge Tag Pharmaceuticals, Kanglong into a 10% rise and stop January 20 morning opening, pharmaceutical stocks CRO track full line surge, Tag Pharmaceuticals, Kanglong into a 10% rise, drug Mingkangde rose nearly 7%, Zhao Yan new drugs rose and stopped.
CRO, or contract research organization, is an academic or commercial scientific institution or individual that conducts all or part of a customer's scientific or medical trials in the course of drug development in order to obtain commercial remuneration.
(Sina Pharmaceutical News) Lilly/Merus reached a $1.6 billion partnership On January 19th, Lilly's company, Loxo Oncology, announced a research partnership and exclusive licensing agreement with Melus N.V. to develop up to three CD3-redirected dual-specific antibody therapies using Melus's proprietary Biclonics® platform and LoxoOlogy Oncology drug design expertise.
terms of the agreement, Merus will lead discovery and early research activities, while Loxo Oncology will be responsible for additional research, development and commercialization activities.
addition to this, Merus is eligible for potential development and commercialization milestone payments of up to $540 million per product, with three products totalling approximately $1.6 billion.
s $550 million acquisition of Mesa Biotech by Seymru Pharmaceutical News follows the announcement of the acquisition of Mesa Biotech for approximately $450 million in cash and a milestone payment of $100 million.
Mesa Biotech is a privately held molecular diagnostics company that develops and sells PCR-based rapid and instant testing platforms for infectious diseases, including SARS-CoV-2, influenza A and B, respiratory syncytial viruses, and Streptococcus A.
about 500 employees and reported revenue of about $45 million in 2020.
(Xinhua) -- The U.S. Supreme Court said on January 19th that it would no longer hear lawsuits betweenix Pharmaceuticals and Gilead Sciences, a subsidiary of Mercadon, after its $2.54 billion patent lawsuit against Gilead was lost.
This means that the appeals court will continue to uphold the previous lower court's ruling in the patent infringement case against Gilead Pharmaceuticals for marketing the lucrative hepatitis C drugs Harvoni and Sovald, and Gilead will not have to pay $2.54 billion in damages to withdraw from the lawsuit.
(Sina Pharmaceutical News) Jieyi Bio completed nearly 200 million yuan B round of financing recently, Jieyi Bio announced the completion of nearly 200 million yuan B round of financing.
this round of financing by Chende capital lead investment, the former jellyfish fund and other investment, next to the next star venture capital, PwC capital, in-body diagnosis of senior industrial personnel and other former shareholders are additional investment.
this round of financing will be mainly used for the registration of infected line medical device products, the development of new products and the promotion of commercial application strategy.
(Arterial Network) Part3 drug news Gritstone Oncology "second generation" new crown vaccine is about to start clinical trials on January 20, Gritstone Oncology announced that it is advancing the development of a second-generation vaccine against the new coronavirus, which has the potential to have long-term protection against the new coronavirus python protein mutants.
has reached a clinical trial agreement with the National Institutes of Allergy and Infectious Diseases, part of the National Institutes of Health, to launch Phase 1 clinical trials in the first quarter of this year.
bill and Melinda Gates Foundation is supporting a preclinical evaluation of the vaccine.
(Pharmaceutical Mingkangde) Jimin Trusted New Coronary and Antibody Initiation Phase 1 Clinical January 20, Jimin Credibility Group announced that its new coronavirus mesothadized antibody - JMB2002 has started Phase 1 clinical trials in Shulan (Hangzhou) Hospital.
JMB2002 is an all-human-specific neutral antibody developed by Jimin Trust Group Shanghai Research Institute, which is intended to be used to prevent and treat new coronavirus infections.
(Pharmaceutical Mission) FDA today approved bayer/ Merca East heart failure new drug market today, the FDA official website information shows that Bayer and Mercadon jointly developed bird nucleotide cyclase agonist Verquvo new drug application has been approved, the treatment of heart failure after the deterioration of the event shot blood score of less than 45% of patients with symptomatic chronic heart failure.
is the first innovative drug approved by the FDA in 2021 and the first soluble bird nucleotide cyclase agonist to treat patients with worsening chronic heart failure.
(Pharmaceutical Mingkangde) Omeros innovative antibody therapy was approved by the FDA on January 20, Omeros announced that the U.S. FDA has accepted the company's biological product licensing application for the study of monoclonal antibody therapy narsoplimab for the treatment of hematopoietic stem cell transplant-related thrombosis microvascular disease.
the BLA priority review at the same time as the FDA and is expected to respond by July 17 this year.
Narsoplimab, also known as OMS721, is a monoclonal antibody with MASSP-2 as its target.
(Pharmaceutical Mingkangde) Youzhiyou BioCD38xCD3 dual-specific antibody new drug approved clinical NMPA drug review center latest publicity, Youzhiyou Bio research and development of "injection recombinant anti-CD38 and CD3 dual-specific antibody" obtained a clinical trial implied license, the adaptive disease is multiple myeloma.
the first clinically approved CD38xCD3 dual-specific antibody in China, according to a press release from Yuzhiyou Bio.
CD38 antigen is a type II transfilm glycoprotein with a size of 46 kDa, and CD38 interacts with the mating body CD31, playing an important role in regulating cell migration, subject-mediated adhesion, and signal conduction.
(Pharmaceutical Mingkangde) Acoustic Pharmaceutical CDK4/6 inhibitors were approved clinically on January 19, CDE official website shows that Synth Pharmaceuticals from G1 Therapeutics introduced CDK4/6 inhibitors "Injection Trilaciclib" approved clinically.
is an innovative drug that was first introduced in August 2020 for a total of $170 million, G1 has filed a new application in the United States for bone marrow protection for patients with small cell lung cancer.
as a bone marrow protector, Trilaciclib protects the patient's bone marrow from chemotherapy and improves the patient's prognostics.
(Insight database) Qilu Pharmaceutical Aykupa ethanolamine tablets listed application was accepted by CDE contractor on January 20, Qilu Pharmaceuticals with imitation of the 4 categories of declared Equipopa ethanolamine tablets market applications were accepted by CDE contractors.
Equopa ethanolamine is an oral biologically available, small molecule plateatoplamin) receptor atrial atrium that interacts with the cross-membrane domain of the human TPO receptor and is clinically used in patients with plate plateiatric reduction and increased risk of bleeding due to clinical conditions.
(Mi net) Baiji Shenzhou introduced IL-6 inhibitor listing application by CDE to accept the State Drug Administration Drug Review Center latest publicity, EUSA Pharma and Baiji Shenzhou jointly submitted two IL-6 inhibitor injection stoxi monoantigen listing application, and was accepted on January 20.
It is worth mentioning that the drug was included in the proposed priority review by CDE just over a week ago for "multi-center Castelman disease adult patients with hiv-negative treatment of human immunodeficiency virus and human herpes virus 8-negative".
(Pharmaceutical Mission) Newforth Bio-Ophthalmology Clinical Application was accepted on January 19, the National Drug Administration Drug Review Center announced that Newforth Bio-Ophthalmology Gene Therapy NR082 eye injection in the declaration of clinical trials and was accepted.
previously, NR082 had